Myriad Genetics (MYGN)
3.19
-0.04 (1.24%)
Upcoming Events
Latest Headlines
Piper Sandler Double Downgrades Myriad Genetics (MYGN) to Underweight, 'Major Strategic Action Likely Needed'
September 1, 2026 3:36 AM - StreetInsider
Myriad Genetics to Present at 2026 Wells Fargo Healthcare Conference
August 27, 2026 9:05 AM - Globe NewsWire
Myriad Genetics (MYGN) PT Lowered to $2.50 at Jefferies
August 20, 2026 3:55 PM - StreetInsider
Myriad Genetics (MYGN) PT Lowered to $3 at Stephens
August 18, 2026 6:31 AM - StreetInsider
Form 4 MYRIAD GENETICS INC For: Aug 16 Filed by: Wheeler Benjamin Richard
August 17, 2026 4:26 PM - SEC Filing
Form SCHEDULE 13G/A MYRIAD GENETICS INC Filed by: GLENVIEW CAPITAL MANAGEMENT, LLC
August 14, 2026 5:00 PM - SEC Filing
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: Vestal Point Capital, LP
August 14, 2026 4:16 PM - SEC Filing
Form SCHEDULE 13G MYRIAD GENETICS INC Filed by: STATE STREET CORP
August 7, 2026 10:10 AM - SEC Filing
Myriad Genetics (MYGN) PT Lowered to $3 at Wells Fargo
August 3, 2026 7:08 AM - StreetInsider
Myriad Genetics (MYGN) PT Lowered to $4 at TD Cowen
July 31, 2026 9:09 AM - StreetInsider
Form 10-Q MYRIAD GENETICS INC For: Jun 30
July 31, 2026 8:02 AM - SEC Filing
Myriad Genetics (MYGN) Misses Q2 EPS by 19c ; Offers Guidance
July 31, 2026 1:08 AM - StreetInsider
Form 8-K MYRIAD GENETICS INC For: Jul 30
July 30, 2026 4:08 PM - SEC Filing
Myriad Genetics cuts 2026 revenue guidance after Q2 miss
July 30, 2026 4:07 PM - StreetInsider
Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability
July 30, 2026 4:05 PM - StreetInsider
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026
July 23, 2026 9:05 AM - StreetInsider
Myriad Genetics launches four-in-one prenatal genetic screen
July 21, 2026 9:05 AM - StreetInsider
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen
July 21, 2026 9:05 AM - StreetInsider
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer
July 2, 2026 9:05 AM - StreetInsider
Form 4 MYRIAD GENETICS INC For: Jun 23 Filed by: Skovronsky Daniel
June 23, 2026 4:25 PM - SEC Filing
Myriad Genetics expands Precise MRD cancer test to three tumor types
June 23, 2026 9:05 AM - StreetInsider
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication
June 23, 2026 9:05 AM - StreetInsider
Myriad Genetics board member Skovronsky resigns
June 23, 2026 8:36 AM - StreetInsider
Form 8-K MYRIAD GENETICS INC For: Jun 17
June 23, 2026 8:32 AM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Jun 11 Filed by: Raha Samraat S.
June 12, 2026 6:06 PM - SEC Filing
Form 4 MYRIAD GENETICS INC For: Jun 11 Filed by: Donnelly Brian J
June 12, 2026 6:06 PM - SEC Filing
TD Cowen notes short interest shifts in life science tools stocks
June 10, 2026 10:50 AM - StreetInsider
Form 4 MYRIAD GENETICS INC For: Jun 08 Filed by: Kumar Rashmi
June 9, 2026 4:21 PM - SEC Filing
Form 144 MYRIAD GENETICS INC Filed by: Kumar Rashmi
June 8, 2026 11:17 AM - SEC Filing
Full Article List
